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Bmi-1 = B lymphoma Mo-MLV insertion region 1; Dsh = Dishevelled; ESA = epithelial-specific antigen; Fu = Fused; GSK = glycogen synthase
kinase; HBEC = human breast epithelial cell; Ihh = indian hedgehog; Ptch = patched; Shh = sonic hedgehog; Smo = smoothened; SuFu = sup-
pressor of fused.
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Abstract
The mammary gland epithelial components are thought to arise
from stem cells that undergo both self-renewal and differentiation.
Self-renewal has been shown to be regulated by the Hedgehog,
Notch, and Wnt pathways and the transcription factor B lymphoma
Mo-MLV insertion region 1 (Bmi-1). We review data about the
existence of stem cells in the mammary gland and the pathways
regulating the self-renewal of these cells. We present evidence
that deregulation of the self-renewal in stem cells/progenitors
might be a key event in mammary carcinogenesis. If ‘tumor stem
cells’ are inherently resistant to current therapies, targeting stem
cell self-renewal pathways might provide a novel approach for
breast cancer treatment.
Introduction
The mammary gland in humans and in other mammals is a
dynamic organ that undergoes significant developmental
changes during pregnancy, lactation, and involution. It is likely
that the cellular repertoire of the human mammary gland is
generated by a stem cell component. These stem cells have a
unique capacity for self-renewal as well as for generating the
three lineages that comprise the lobulo-alveolar structure of
the adult gland: myoepithelial cells forming the basal layer of
ducts and alveoli, ductal epithelial cells lining the lumen of
ducts, and alveolar epithelial cells synthesizing milk proteins
[1,2]. Under the regulation of systemic hormones, as well as
local stromal epithelial interactions, these cells proliferate
extensively, differentiate during each pregnancy and lactation,
and undergo apoptosis during mammary involution [2]. It has
been shown previously that a subset of the luminal epithelial
cells could convert to myoepithelial cells in culture, signifying
the possible existence of a progenitor cell [3]. Recently,
Stingl and colleagues characterized the multipotent epithelial
cells in the normal adult breast [4]. In their experimental
system, two distinct types of human breast epithelial cell
(HBEC) progenitor population could be distinguished on the
basis of their differential expression of the MUC-1 glyco-
protein CALLA/CD10 and epithelial-specific antigen (ESA).
MUC-1+/CALLA–/ESA+ progenitors (luminal restricted
progenitor, or alveolar progenitor) expressed typical luminal
epitopes (keratin 8/18, keratin 19, MUC-1, and ESA) and
showed low levels of expression of myoepithelial epitopes
(keratin 14 and CD44v6). The second type of progenitor,
MUC-1– to ±/CALLA± to +/ESA+ (bipotent progenitor, or ductal
progenitor), generated mixed colonies of both luminal and
myoepithelial cells when seeded in two-dimensional and
three-dimensional cultures. Furthermore, they suggested that
the MUC-1+/CALLA–/ESA+ and the MUC-1– to ±/CALLA± to +/
ESA+ progenitors are candidate in vivo alveolar and ductal
progenitors, respectively [4]. HBEC clonal heterogeneity has
also been reported by others [5]. Such clonal heterogeneity
might be indicative of an underlying stochastic mechanism
regulating HBEC differentiation independently of the
presence of factors (such as epidermal growth factor and
insulin) that might be required to support the viability and/or
stimulate the proliferation of these cells [4].
There is also increasing evidence that stem cells might be the
targets of transformation during carcinogenesis. Carcinomas
are believed to arise through a series of mutations that occur
over many years. Adult stem cells are slowly dividing, long-
lived cells, which by their very nature are exposed to
damaging agents for long periods. They may therefore
accumulate mutations that result in transformation [6]. In favor
of the role of stem cells in carcinogenesis comes the
observation that normal stem cells and cancer stem cells
share several important properties such as the capacity for
self-renewal, the ability to differentiate, active telomerase and
anti-apoptotic pathways, increased membrane transporter
activity, anchorage independence and ability to migrate and
form metastasis. The transformation of mammary stem and
progenitor cells also contributes to the generation of tumor
heterogeneity. There is now evidence for the existence of
‘tumor stem cells’ in human leukemias, myeloma, and brain
tumors, as well as in breast carcinomas [7–12].
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A unique property of stem cells is their ability to undergo self-
renewal divisions. In normal organogenesis this process is
tightly regulated. The deregulation of self-renewal might be
one of the key events involved in carcinogenesis. Indeed,
pathways involving cell signaling pathways and transcription
factors involved in the self-renewal of normal stem cells have
all been implicated in carcinogenesis. These pathways
include Hedgehog, Notch and Wnt, as well as the
transcription factor B lymphoma Mo-MLV insertion region 1
(Bmi-1). In this article we review evidence that these
pathways are involved in both stem cell self-renewal and
carcinogenesis, which provides support for the concept that
breast carcinogenesis results from the deregulation of self-
renewal pathways of normal mammary stem cells. We then
discuss the implications of these studies for the development
of novel therapies that target these self-renewal pathways.
Mammary stem cells
Stem cells are defined by their ability to undergo self-renewal,
as well as multi-lineage differentiation. This self-renewal can
be either asymmetric or symmetric. Self-renewal is
distinguished from other proliferative processes in that at
least one of the progeny of self-renewal is identical to the
initial stem cell. In all other replicative processes, the progeny
of division undergo a series of differentiation events [13]. In
asymmetric stem cell self-renewal, one of the two progeny is
identical to the initial stem cell, whereas the other cell is a
committed progenitor cell, which undergoes cellular
differentiation. Because the product of an asymmetric self-
renewal division is one stem cell and one differentiated cell,
this process maintains stem cell number. In contrast,
symmetric self-renewal results in the production of two stem
cells; by its very nature this results in stem cell expansion. The
processes that regulate the balance between asymmetric and
symmetric divisions of stem cells are poorly defined, but
recent evidence indicates a role for p53 and inosine
monophosphate dehydrogenase [14]. Although stem cells
themselves are slowly dividing, progenitor cells derived from
them are highly proliferative [15]. This expanding progenitor
cell also has the ability to differentiate into the lineages
comprising the adult tissue.
The existence of self-renewing multipotent mammary stem
cells has been clearly demonstrated by transplantation
studies in mice and rats [16–18]. Fragments of mammary
epithelium marked with mouse mammary tumor virus were
able to regenerate a new gland after transplantation into a
mammary fat pad cleared of its epithelial components [19].
Serial transplantation of the clonally derived outgrowth
recapitulated the entire functional repertoire of the gland,
demonstrating the existence of self-renewing and multipotent
mammary stem cells. A recent study in mice combining long-
term labeling in vivo using bromodeoxyuridine with
immunosorting and transplantation showed that mammary
stem cell antigen-1 (SCA-1)-positive population is enriched in
progenitor cells able to regenerate the gland in vivo [20].
The cultivation of normal mammary stem and progenitor cells
has been limited by the lack of suitable systems that permit
the propagation of these cells in an undifferentiated state.
When primary cultures of mammary epithelium from rodents
or humans are cultured on solid substrata, they undergo
limited replication and differentiate in a process that is
regulated by hormonal factors, extracellular matrix, and
cell–cell interactions [21–23]. A major advance in neural
stem cell research was achieved when it was found that an
undifferentiated multipotent population of neural cells can be
grown in suspension as neurospheres [24]. On the basis of the
hypothesis that stem cells might be able to grow in anchorage-
independent conditions, we developed a novel culture system
for human mammary epithelial stem and progenitor cells. We
demonstrated that human mammary epithelial cells, isolated
from reduction mammoplasties, when grown on non-adherent
substrata in the presence of growth factors, generate spherical
colonies that we have termed ‘mammospheres’ [25], which are
different from the three-dimensional structured mammospheres
cultured from mammary organoids plated on extracellular matrix
[26]. In our culture system in vitro, mammospheres are grown
in suspension and are enriched in mammary stem/progenitor
cells capable of self-renewal and multi-lineage differentiation
(Fig. 1). We have also shown that mammospheres contain cells
capable of clonally generating complex functional ductal
alveolar structures in reconstituted three-dimensional culture
systems in Matrigel (Fig. 1), and when combined with human
mammary fibroblasts they are able to reconstitute the mammary
tree in the cleared mammary fat pad of NOD/SCID mice
(Fig. 1; Liu S and Mantle I et al., manuscript in preparation). The
use of this culture system has enabled us to begin to elucidate
the pathways that regulate the self-renewal and differentiation
of normal mammary stem and progenitor cells (see below).
Tumor stem cells
There is increasing evidence that both stem and progenitor
cells may be the targets of transformation during
carcinogenesis. As described above, normal stem cells and
cancer cells share several important properties, including the
ability to self-renew and undergo differentiation. However, the
mutations and/or epigenetic events involved in carcino-
genesis may disregulate these pathways. Ensuing aberrant
differentiation might in turn contribute to the phenotypic
cellular heterogeneity found in tumors. Using different
systems, several investigators have demonstrated that only a
minority of cells in human cancers are capable of self-
renewal. This has been most convincingly demonstrated by
examining the ability of subpopulations of tumor cells
identified by cell surface markers to form tumors when
transplanted into immunosuppressed NOD/SCID mice. This
approach was first successfully used to demonstrate the
existence of leukemic stem cells [27].
We have used a similar approach to identify a subpopulation
of human mammary cancer cells bearing the phenotype
ESA+CD44+CD25–/lowLineage– that have the properties of88
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breast cancer ‘stem cells’. As few as 100 of these cells,
isolated from primary human breast carcinomas or metastatic
lesions, are able to form tumors reproducibly in NOD/SCID
mice. In contrast, tens of thousands of cells that do not bear
this phenotype are unable to generate tumors in this model.
Furthermore, consistent with a stem cell model is the
observation that tumor stem cells are able to be serially
passaged in NOD/SCID mice, each time generating a stem
cell population, as well as the more differentiated non-
tumorigenic cells forming the bulk of the tumor [27]. These
‘tumor stem cells’ thus share the properties of self-renewal
and differentiation with their normal stem cell counterparts,
although in tumors these processes are deregulated.
Recent studies have provided evidence for the existence of
‘tumor stem cells’ in human multiple myeloma and brain tumors
in addition to acute leukemias and breast cancer [28,29]. An
alternative model to the ‘tumor stem cells’ model is that
cancers arise and evolve through stochastic mutations that are
then expanded through clonal selection. Genetic instability and
clonal selection undoubtedly do contribute to tumor
heterogeneity and progression. However, the tumor stem cell
model does not exclude the importance of these stochastic or
selective events in tumor evolution. Both may in fact be
operative in both tumorigenesis and tumor progression, and
contribute to the heterogeneity found in cancer.
There has been some controversy about the nature of the
cells that serve as targets of transformation. In a variety of
malignancies, evidence for the clonal generation of tumors
that display markers of multiple lineages has provided
evidence for the stem cell as the cell of origin. However, in
other cases, such as acute promyelocitic leukemia and
chronic myelogenous leukemia, there is evidence for the
transformation of progenitor cells. The transformation of
progenitor cells might require mutations that allow them to
undergo self-renewal, normally a process limited to stem
cells. Indeed, we have recently proposed that the
transformation of mammary stem and/or progenitor cells
might result in the heterogeneity of breast cancer types
between different patients, reflected in molecular profiling
data [6]. The molecular profile of tumors might be determined
by both the cell of origin as well as the particular mutation
profile, in turn determining the differentiation pattern of these
cells, which comprise the bulk of the tumor. These categories
defined by molecular profiling might have important
diagnostic and prognostic implications. Regardless of the
cells of origin, the common feature that might be required for
transformation is the ability of the target cell to undergo self-
renewal and subsequent expansion.
Thus, an understanding of the pathways that govern the self-
renewal of normal stem cells, and the ways in which these
Figure 1
Experimental design for assessing self-renewal and differentiation potential of cells grown as mammospheres. (a) Self-renewal is assessed by
evaluating the ability of mammosphere-derived cells to form new spheres, containing multipotent cells. (b) Differentiation into all the three mammary
lineage types on collagen in the presence of serum [immunostained with lineage-specific markers: brown, ductal epithelial (ESA); purple,
myoepithelial (CD10); red, alveolar (β-casein)]. (c) Generate complex ductal-alveolar structures in three-dimensional Matrigel culture. 
(d) Differentiation and self-renewal in vivo are tested by implanting human mammary epithelial cells into the cleared mammary fat pads of
immunodeficient mice (NOD/SCID mice). EGF, epidermal growth factor.89
pathways are deregulated during carcinogenesis, is of utmost
importance. Several pathways found to have important roles
in development and a transcription factor Bmi-1 have been
shown to be involved in the regulation of stem cell self-
renewal and differentiation. These pathways include
Hedgehog, Notch, and Wnt. We review the role of these
signaling pathways in stem cell self-renewal as well as
evidence that these same pathways are important in the
normal development of the mammary gland. We then discuss
evidence that deregulation of these pathways is important in
mammary carcinogenesis.
Hedgehog signaling
The hedgehog signaling pathway was first identified in
Drosophila, where it is required for early embryo patterning. In
recent years, great progress has been made in understanding
the hedgehog signaling network [30,31]. This pathway is
depicted graphically in Fig. 2. Three hedgehog ligands have
been identified in mammals: Sonic Hedgehog (Shh), Desert
Hedgehog (Dhh), and Indian Hedgehog (Ihh), all of which are
secreted glycoproteins. After secretion, these ligands bind to
the hedgehog-interacting protein 1 (Hip1) and Patched
(Ptch), which are transmembrane receptors for these ligands.
Two transmembrane proteins, Ptch and Smoothened (Smo),
form the receptor complex in the absence of ligands. Ptch
binds to Smo and blocks its function. This inhibition is
relieved in the presence of ligands, and Smo interacts in a
signaling cascade that results in activation of the transcription
factors Gli1, Gli2, and Gli3. Gli proteins in turn translocate
into the nucleus and control target gene transcription. In the
absence of ligands, Gli proteins are tethered to the
cytoskeleton by interacting with a multiprotein complex that
includes Fused (Fu) and Suppressor of Fused (SuFu) [32].
Gli regulates the transcription of several genes, including
those controlling cell proliferation such as cyclin D, cyclin E,
Myc, components of the epidermal growth factor pathway,
and angiogenesis components including platelet derived-
growth factor and vascular endothelial growth factor.
Recent studies have indicated that hedgehog signaling is
important in embryonic mammary gland induction, ductal
morphogenesis, and alveolar development. A critical role for
hedgehog signaling in mediating epithelial stromal
interactions during ductal development has been shown by
the genetic analysis of two hedgehog signal transduction
network genes, Ptch1 and Gli-2. Disruption of either gene
leads to similar, yet distinct, defects in ductal morphogenesis
that are mainly ductal dysplasias similar to the hyperplasias of
the human breast. We have used the mammosphere-based
culture system to examine the role of hedgehog signaling in
mammary cell fate determination. Our data show that the
addition of recombinant Shh can stimulate the formation of
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Figure 2
A schematic diagram for the hedgehog (HH) signaling pathway. Ligands, such as Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), and Desert
Hedgehog (Dhh), are secreted by signaling cells and bind the transmembrane receptor patched (Ptch) in HH responding cells. In the absence of
ligands, Ptch binds to Smoothened (Smo) and blocks Smo’s function, whereas this inhibition is relieved in the presence of ligands, and Smo
initiates a signaling cascade that results in the release of transcription factors Glis from cytoplasmic proteins fused (Fu) and suppressor of fused
(SuFu). In the inactive situation, SuFu prevents Glis from translocating to the nucleus; in the active situation, Fu inhibits SuFu and Glis are released.
Gli proteins translocate into the nucleus and control target gene transcription. The red lines and the agents in red show the inhibitors of this
pathway with potential therapeutic value.90
primary and secondary mammospheres and can increase
mammosphere size, a process that can be blocked by the
Smo inhibitor cyclopamine (Liu S et al., manuscript in
preparation). These studies suggest that hedgehog signaling
is involved in mammary stem cell self-renewal.
The importance of hedgehog signaling in carcinogenesis has
been demonstrated by the fact that many of the genes
involving hedgehog signaling are known oncogenes,
including Smo, Shh, Gli-1, and Gli-2, or that Ptch1 can
function as a tumor suppressor. Mutations in these genes
have been linked to the development of many common
cancers, which were shown to be dependent on activated
Hedgehog signaling [31]. Mutations in hedgehog signaling
were first described in Gorlin syndrome and basal
carcinomas of the skin. More recently, an important role for
hedgehog signaling has been shown in medulloblastoma,
prostate, and pancreatic carcinomas [33,34]. Similarities
between hedgehog mutation-induced ductal dysplasias and
human breast pathologies suggest a role for altered
hedgehog signaling in the development of mammary cancer.
There is also evidence that altered hedgehog signaling has a
direct role in the neoplastic progression of the mammary
gland. One study showed Ptch1 mutation in two of seven
human breast cancers [35]. Recently, a natural polymorphism
in the 3′ end of the Ptch1 coding region (C3944T;
Pro1315→Leu) has been linked to increased breast cancer
risk associated with oral contraceptive use [36]. Evidence for
a role in breast cancer also comes from published genetic
studies in mice showing hyperplastic defects in the mammary
gland of ∆Ptch1 + and ∆Gli1 mutants [37]. Recently, Kubo
and colleagues showed that a specific inhibitor of hedgehog
signaling, cyclopamine, is able to inhibit the growth of
mammary carcinoma cells in vitro [38].
Notch signaling
Notch transmembrane receptors are part of signaling
pathways that are crucial in the regulation of the fate of cells
in a variety of tissues [39]. The Notch proteins, represented
by four homologues in mammals, Notch 1 to Notch 4, are
expressed in a variety of stem or early progenitor cells. They
interact with several surface-bound ligands (DSL ligands:
Delta, Delta like, Jagged1 and Jagged2 in vertebrates) [39].
These interactions are in turn regulated by a number of
modifiers that form the fringe family [40]. Upon ligand
binding, Notch receptors are activated by serial cleavage
events involving members of the ADAM (for ‘a disintegrin and
metalloproteinase’) protease family, as well as an
intramembrane cleavage regulated by γ-secretase
(presenilin). This intramembrane cleavage is followed by
translocation of the intracellular domain of Notch to the
nucleus, where it acts on downstream targets (Fig. 3).
Activation of the Notch pathway results in changes in cell
fate, including self-renewal of stem cells or differentiation
along a particular lineage [41]. The Notch pathway was
shown to be involved in the normal development of the
mammary gland. In vitro, overexpression of the constitutively
active form of Notch4 inhibits the differentiation of normal
breast epithelial cells. Smith and colleagues also
demonstrated that, in vivo, Notch4 has an important role both
in normal mammary development and in carcinogenesis.
Transgenic mice harboring a constitutively active Notch4
under the regulation of mouse mammary tumor virus promoter
exhibited arrested mammary gland development, and
eventually developed poorly differentiated adenocarcinomas.
Notch1 is also a downstream effecter of oncogenic Ras and
its signaling activation maintains the neoplastic phenotype in
human Ras-transformed cells [42].
We have recently used the mammosphere system described
above to study the role of Notch signaling in mammary cell
fate determination. Our findings suggested that Notch
signaling is active in several distinct developmental stages of
the mammary gland and that Notch acts as a regulator of
asymmetric cell fate decisions. Notch activation promoted the
self-renewal of stem cells, whereas in later stages of
development it biased cell fate decisions in mammary
progenitor cells toward the adoption of a myoepithelial cell
fate versus an epithelial cell fate [6]. Musashi is a positive
regulator of Notch signaling through an interaction with Numb
mRNA and repression of its translation [43]. More recently,
Musashi-1 and Notch1 were shown to be the two key
regulators of asymmetric cell division in human breast
epithelial stem cells [44,45]. These findings about the role of
Notch in promoting the self-renewal of mammary stem cells,
in addition to previous observations that it can function as a
proto-oncogene [46,47], suggest that abnormal Notch
signaling might be involved in carcinogenesis, through the
deregulation of normal mammary stem cell self-renewal.
Wnt signaling
The Wnt pathway regulates cell fate determination in a
number of tissues, including the mammary gland. The Wnts
are a family of secreted proteins. So far, the most well-
characterized Wnt signaling pathway is called the canonical
Wnt pathway, in which Wnt ligands signal through the
stabilization of β-catenin. More recently, several β-catenin-
independent Wnt signaling pathways, known as non-
canonical, have been shown to be crucial for different
aspects of vertebrate embryo development [48]. In the
canonical Wnt pathway, Wnt proteins bind to a family of
Frizzled receptors in a complex with the low-density
lipoprotein receptor-related proteins 5 and 6 (LRP5/6) [49].
Activation of these receptors results in the accumulation of
intracellular  β-catenin. In the absence of Wnt signaling, β-
catenin remains in the cytoplasm, where it forms a complex
with other proteins, including the tumor suppressor
adenomatous polyposis coli and axin, and well as glycogen
synthase kinase (GSK)-3β. GSK-3β is able to phosphorylate
β-catenin, which targets the protein for ubiquitin-mediated
degradation. When the Wnt pathway is activated, GSK-3β is
inhibited, blocking β-catenin phosphorylation. Unphosphory-
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lated  β-catenin is stable and translocates to the nucleus,
where it binds to and activates the transcription factors T cell
factor/lymphoid enhancer factor (TCF/LEF), which then
activate a variety of downstream target genes (Fig. 4a).
The noncanonical Wnt signaling pathway [48] involves Frizzled
receptors and the proteoglycan co-receptor Knypek. A
cytoplasmic signal transduction protein Dishevelled (Dsh)
localizes to the cell membrane through its DEP domain. Dsh
activates Rho through the bridging molecule Daam1. The
precise roles of Rho versus other Rho-family small GTPases
such as Rac and Cdc42 remain unclear, as is the potential role
of the JNK pathway. Dsh can also stimulate calcium flux and
sequentially activates the calcium-sensitive kinases protein
kinase C and calmodulin-dependent protein kinase II (Fig. 4b).
Recently, several studies have provided evidence for a direct
role of Wnt signaling in the self-renewal of hematopoietic,
epidermal, and gut stem cells [50,51]. Retroviral transduction
of activated β-catenin results in increased epidermal stem cell
self-renewal and decreased differentiation. A direct role for
dysfunction of this pathway in cancer was established by
experiments in transgenic mice that showed that activation of
the Wnt signaling pathway in epidermal stem cells leads to
epithelial cancers [52]. Furthermore, in breast cancers, it has
been demonstrated that there is upregulation of the
uncomplexed transcriptionally active form of β-catenin without
mutations afflicting downstream components [53]. A role for
Wnt signaling in stem cell self-renewal of mammary stem
cells was suggested by recent studies of Alexander and
colleagues, who used transgenic mice to show that
overexpression of Wnt ligands in mammary stroma or
activated β-catenin in mammary epithelium leads to increased
numbers of mammary stem cells [54]. Studies linking this
process to mammary carcinogenesis include those showing
that mammary stem cells and progenitors might be targets for
oncogenesis by Wnt 1 signaling elements [55].
Bmi-1
Bmi-1 is a transcriptional repressor belonging to the
polycomb (PCG) group of transcription factors. It was first
identified in a B-cell lymphoma [56]. Recently, Bmi-1 has
been shown to be a key regulator of the self-renewal of both
normal and leukemic stem cells [57,58]. Bmi-1 has also been
shown to be important in neuronal stem cell self-renewal [59].
Several recent studies have suggested a link between Bmi-1
and mammary carcinogenesis. Bmi-1 was shown to be
overexpressed in several human breast cancer cell lines.
Furthermore, it was found that Bmi-1 regulates telomerase
expression in mammary epithelial cells. These studies
suggest that Bmi-1 might have a role in mammary carcino-
genesis [60]. Although the mechanisms by which Bmi-1
regulates stem cell self-renewal remain unclear, one important
gene silenced by Bmi-1 might be P-16 [58]. However, P-16
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Figure 3
A schematic diagram for the Notch signaling pathway. Upon binding of the DSL ligand, Notch signaling is modulated by fringe, and Notch
receptors are activated by serial cleavage events involving members of the ADAM (for ‘a disintegrin and metalloproteinase’) protease family, as well
as an intramembrane cleavage regulated by γ-secretase (presenilin ). This intramembrane cleavage is followed by translocation of the intracellular
domain on Notch to the nucleus, where it acts on downstream targets. CBF, C promoter binding factor; HDAC, histone deacetylase; HAT, histone
acetyltransferase.92
only partly mediated the effects of Bmi-1 proteins in neural
stem cells, thereby suggesting that other factors might
participate in Bmi-1’s effects on stem cell self-renewal.
Recent studies by Tlsty and colleagues [61] have suggested
that the epigenetic silencing of P-16 might be an important
event in early mammary carcinogenesis. Together, these
studies suggest that normal stem cell self-renewal might be
regulated through Bmi-1, partly mediated through the
repression of P-16. During carcinogenesis, this process
might be deregulated by the epigenetic silencing of P-16
through methylation of the P-16 promoter [61].
Interaction between self-renewal pathways
Although we have described signaling pathways that regulate
stem cell self-renewal, individually it is clear that in vivo there
are extensive interactions between the pathways. For
instance, there is evidence for interaction between Hedgehog
signaling and Notch signaling. One study provided evidence
that secreted Shh might be involved in reinforcing the cell
fate switch executed by Notch [62]. Moreover, a recent study
presented intriguing evidence that Notch signaling regulates
Gli-2 expression in mouse skin, and inactivation of the Notch-
1 gene in epidermis induces sustained expression of Gli-2
resulting in the formation of basal carcinoma-like tumors [63].
Recently we used our mammosphere-derived culture systems
to examine the relationship between the hedgehog pathway
and the Notch pathway, and we found that the activation of
the Notch pathway resulted in the subsequent activation of
the hedgehog pathway, including increased expression of
Ptch and Gli. This activation could be blocked by γ-secretase
inhibitor, which inhibits Notch signaling (Liu S et al.,
manuscript in preparation). These studies suggest that
hedgehog acts downstream of Notch. In contrast, one study
showed that Shh acts upstream of Notch to determine
arterial cell fate during arterial endothelial differentiation [64].
Furthermore, we have evidence that activation of hedgehog
pathway by the hedgehog ligands (Shh or Ihh) increased the
expression of the Notch pathway target, HES1, in the
mammospheres, and this effect could be blocked by the
hedgehog inhibitor cyclopamine (Liu S et al., manuscript in
preparation). Together, these studies indicate that Hedgehog
and Notch might form a feedback loop regulating normal
development.
Furthermore, deregulation of this loop might be involved in
cancer formation. In the skin, the activation of two markers of
active Wnt signaling, β-catenin and LEF-1, are associated
with Notch-dependent transformation [65]. The activation of
Smo might initiate processes during which transcription
factors belonging to the Gli family are activated, and modify
the transcription of Ptch and Wnt [65]. Wnt regulation has
previously been observed in human basal carcinomas,
indicating that tumor progression is mediated by interactions
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Figure 4
A schematic diagram for the Wnt signaling pathway. (a) The canonical Wnt/β-catenin pathway. Canonical Wnt signaling requires the Frizzled (Fz)
and low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6) co-receptors to activate Dishevelled (Dsh). Then Dsh inhibits the activity of
the β-catenin destruction complex (adenomatous polyposis coli (APC), axin, and glycogen synthase kinase-3 (GSK-3)), which phosphorylates β-
catenin in the absence of the ligands. β-Catenin is stabilized and translocated to the nucleus, where it recruits transactivators to  high mobility group
(HMG)-box DNA-binding proteins of the lymphoid enhancer factor/T cell factor (LEF/TCF) family. (b) The noncanonical Wnt signaling pathway.
Noncanonical Wnt signaling requires Frizzled receptors and the proteoglycan co-receptor Knypek. In this pathway, Dsh localizes to the cell
membrane through its DEP domain. A main branch downstream of Dsh involves the small GTPases of the Rho family. Dsh activation of Rho requires
the bridging molecule Daam1. Dsh can also stimulate calcium flux and the activation of the calcium-sensitive kinases protein kinase C (PKC) and
calmodulin-dependent protein kinase II (CanKII). At the end, the activation of this pathway induces the complex and dynamic cellular response.93
of distinct signaling pathways that regulate organ develop-
ment during embryogenesis. All of these pathways are also
intimately involved in the regulation of stem cell self-renewal.
Interestingly, Bmi-1 expression was rapidly increased after
the addition of Shh or after the overexpression of the Shh
target Gli in cerebellar granular cells, which implies that Bmi-
1 is a downstream target in the Shh pathway [66].
Overexpression of Bmi-1 correlated with overexpression of
Ptch and SuFu, which suggests at least a partial activation of
the Hedgehog pathway in Bmi-1 overexpression tumors [66].
In our preliminary data we showed that both the activation of
Hedgehog pathway by Shh or Ihh and the activation of the
Notch pathway by DSL resulted in the expression of Bmi-1 in
the mammosphere culture system, and the induction of Bmi-1
expression could be blocked by the pathway-specific
inhibitors cyclopamine in the Hedgehog pathway and γ-
secretase inhibitor in the Notch pathway, respectively (Liu S
et al., manuscript in preparation).
Together, these studies demonstrate extensive interaction
between the signaling pathways that regulate stem cell self-
renewal. These interactions are depicted graphically in Fig. 5.
In this model, Hedgehog and Notch signalings form a loop
regulating normal development; both of these pathways might
regulate the stem cell self-renewal by upregulating the
expression of Bmi-1, which has been identified as a regulator
of stem cell self-renewal. It has also been shown that the Wnt
pathway can act downstream of both the Hedgehog pathway
and the Notch pathway, and the Wnt pathway has been
shown to be a regulator of stem cell self-renewal. However, it
has not been determined whether the Hedgehog pathway
and the Notch pathway can regulate stem cell self-renewal
through downstream targets other than Bmi-1. Further
elucidation of this model will be required for an understanding
of the elements that regulate normal and malignant mammary
stem cell self-renewal.
Conclusions and clinical implications
In this review we have presented evidence that carcino-
genesis in the mammary gland, and in other organs, might
result from transformation of stem and/or progenitor cells by
the deregulation of self-renewal pathways. These pathways
include Hedgehog, Notch, Wnt, and the transcription factor
Bmi-1. The hypothesis that mammary carcinogenesis results
from the deregulation of normal stem cell self-renewal
pathways suggests that components of these pathways
might provide attractive targets for therapeutic development.
This is of great importance because current therapies may be
limited in their effectiveness by virtue of the fact that they
might selectively target the more differentiated cells in a
tumor. Tumor stem cells, by virtue of their slow cell cycle
kinetics, transporter proteins, and anti-apoptotic mechanisms,
might be resistant to these treatments (reviewed in [67]). The
targeting of self-renewal pathways might provide a more
specific approach to the elimination of cancer stem cells. A
potential challenge in this regard is the development of
therapies that selectively affect cancer stem cells while
sparing normal stem cells that may rely on similar
mechanisms for self-renewal. Recent studies have shown that
inhibitors of hedgehog signaling, such as cyclopamine, can
inhibit mammary tumor cells in vitro [38]. Furthermore, a
small-molecule inhibitor of the Shh pathway – a Hedgehog
antagonist (HhAntag) – has recently been reported to
eliminate medulloblastoma in transgenic mice without
apparent systemic toxicity [68]. These studies suggest that
strategies aimed at targeting cancer stem cell self-renewal
might provide a novel therapeutic approach for the treatment
of breast and other cancers.
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